PD-1とPD-L1阻害剤市場：製品別、流通チャネル別-2025～2030年の世界予測

PD-1とPD-L1阻害剤市場は、2023年に371億1,000万米ドルと評価され、2024年には446億1,000万米ドルに達すると予測され、CAGR 20.59％で成長し、2030年には1,376億5,000万米ドルに達すると予測されています。

プログラム死-1（PD-1）とプログラム死-リガンド1（PD-L1）阻害剤は、腫瘍細胞を攻撃する免疫系を再活性化するのに役立つため、様々ながんの治療において極めて重要です。これらの阻害剤の必要性は、従来の治療に反応しない患者に治療の選択肢を提供する能力から生じ、個別化医療へのシフトを意味します。その用途は、メラノーマ、非小細胞肺がん、腎細胞がんなど、多くのがんに及びます。最終用途には、革新的ながん治療法に取り組む病院、クリニック、研究機関が含まれます。PD-1阻害剤とPD-L1阻害剤の市場は、世界のがん罹患率の上昇、研究資金の増加、免疫療法に対する意識の高まりが主要要因となっています。また、新規阻害剤の共同開発や商業化のための戦略的提携や共同研究も、重要な成長の一翼を担っています。新たなビジネス機会は、有効性を高め、適用範囲を拡大しうる併用療法の探求にあります。しかし、高い治療費、規制上の課題、患者への普及を制限する副作用の可能性などが成長の妨げとなっています。競合情勢は厳しく、競合を維持するためには多額の研究開発投資が必要です。革新的な成長セグメントとしては、安全性プロファイルと有効性を改善した次世代阻害剤の開発、より良い患者層別化と治療のカスタマイズのためのバイオマーカーの研究などが挙げられます。企業は、医療のインフラが改善しつつある新興市場への地理的な足跡の拡大や、治療費をより安価にするための戦略の採用に注力すべきです。市場競争は激しく、急速な技術進歩の影響を受けるため、常に研究の最先端を維持し、ビジネスモデルの俊敏性を維持することが鍵となります。戦略的提言としては、個別化医療ソリューションのための研究開発への投資、戦略的協力関係の確保、費用対効果の高い生産・流通チャネルによる市場アクセスの強化などが挙げられます。

市場力学：急速に進化するPD-1とPD-L1阻害剤市場の主要市場洞察を公開

PD-1とPD-L1阻害剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢者の増加と相まって増加するがんの有病率
  • 患者支援プログラムの存在感の高まり
  • 国民の意識の高まりと医療費用の増加
• 市場抑制要因
  • がん免疫療法にかかるコストの高さ
• 市場機会
  • pd1阻害剤とpdl1阻害剤の研究活動の活発化
  • がんスクリーニング法の技術革新と進歩
• 市場課題
  • 厳しい規制シナリオ

ポーターのファイブフォース：PD-1とPD-L1阻害剤市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：PD-1とPD-L1阻害剤市場における外部からの影響の把握

外部マクロ環境要因は、PD-1とPD-L1阻害剤市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：PD-1とPD-L1阻害剤市場における競合情勢の把握

PD-1とPD-L1阻害剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：PD-1とPD-L1阻害剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、PD-1とPD-L1阻害剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：PD-1とPD-L1阻害剤市場における成功への道筋を描く

PD-1とPD-L1阻害剤市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん罹患率の増加と高齢者の増加
    • 患者支援プログラムの拡大
    • 国民の意識の高まりと医療費の増加
  • 抑制要因
    • がん免疫療法の高額な費用
  • 機会
    • PD1とPDL1阻害剤の調査活動の増加
    • がん検査の技術革新と進歩
  • 課題
    • 厳しい規制シナリオ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 PD-1とPD-L1阻害剤市場：製品別

• イントロダクション
• アテゾリズマブ
• アベルマブ
• デュルバルマブ
• ニボルマブ
• ペムブロリズマブ

第7章 PD-1とPD-L1阻害剤市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第8章 南北アメリカのPD-1とPD-L1阻害剤市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋のPD-1とPD-L1阻害剤市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのPD-1とPD-L1阻害剤市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Akeso Inc.
• Alphamab Oncology
• Amgen Inc.
• AstraZeneca PLC
• BeiGene Ltd.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline PLC
• Innovent Biologics Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. PD-1 & PD-L1 INHIBITORS MARKET RESEARCH PROCESS
• FIGURE 2. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PD-1 & PD-L1 INHIBITORS MARKET DYNAMICS
• TABLE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 25. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 104. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

The PD-1 & PD-L1 Inhibitors Market was valued at USD 37.11 billion in 2023, expected to reach USD 44.61 billion in 2024, and is projected to grow at a CAGR of 20.59%, to USD 137.65 billion by 2030.

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are pivotal in the treatment landscape for various cancers as they help in reactivating the immune system to attack tumor cells. The necessity of these inhibitors arises from their ability to provide therapeutic options to patients who may not respond to traditional treatments, signifying a shift towards personalized medicine. Their application spans across numerous cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma, among others. The end-use scope involves hospitals, clinics, and research institutes working towards innovative cancer treatment modalities. The market for PD-1 and PD-L1 inhibitors is primarily driven by the rising incidence of cancer globally, increased research funding, and the growing awareness about immunotherapies. Strategic partnerships and collaborations for co-development and commercialization of novel inhibitors also play a crucial growth role. Emerging opportunities lie in exploring combination therapies, which could enhance efficacy and extend their application scope. However, growth is impeded by high treatment costs, regulatory challenges, and potential side effects that can limit patient adoption. The competitive landscape is challenging with significant R&D investments needed to stay competitive. Innovational growth areas include the development of next-generation inhibitors with improved safety profiles and efficacy, as well as research into biomarkers for better patient stratification and treatment customization. Businesses should focus on expanding their geographical footprint into emerging markets where healthcare infrastructure is improving and adopting strategies to make treatments more affordable. As the market is competitive and subject to rapid technological advancements, staying at the forefront of research and maintaining agility in business models will be key. Strategic recommendations include investing in R&D for personalized medicine solutions, securing strategic collaborations, and enhancing market accessibility through cost-effective production and distribution channels.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PD-1 & PD-L1 Inhibitors Market

The PD-1 & PD-L1 Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cancer coupled with growing geriatric population
  • Growing presence of patient assistance programs
  • Rising public awareness and increasing healthcare expenses
• Market Restraints
  • High cost of cancer immunotherapy
• Market Opportunities
  • Increasing research activities in pd1 and pdl1 inhibitors
  • Technological innovations and advancements in cancer screening procedures
• Market Challenges
  • Stringent regulatory scenario

Porter's Five Forces: A Strategic Tool for Navigating the PD-1 & PD-L1 Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PD-1 & PD-L1 Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PD-1 & PD-L1 Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PD-1 & PD-L1 Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PD-1 & PD-L1 Inhibitors Market

A detailed market share analysis in the PD-1 & PD-L1 Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PD-1 & PD-L1 Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PD-1 & PD-L1 Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PD-1 & PD-L1 Inhibitors Market

A strategic analysis of the PD-1 & PD-L1 Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PD-1 & PD-L1 Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca PLC, BeiGene Ltd., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Innovent Biologics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the PD-1 & PD-L1 Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Atezolizumab, Avelumab, Durvalumab, Nivolumab, and Pembrolizumab.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer coupled with growing geriatric population
    • 5.1.1.2. Growing presence of patient assistance programs
    • 5.1.1.3. Rising public awareness and increasing healthcare expenses
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of cancer immunotherapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing research activities in pd1 and pdl1 inhibitors
    • 5.1.3.2. Technological innovations and advancements in cancer screening procedures
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory scenario
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. PD-1 & PD-L1 Inhibitors Market, by Product

• 6.1. Introduction
• 6.2. Atezolizumab
• 6.3. Avelumab
• 6.4. Durvalumab
• 6.5. Nivolumab
• 6.6. Pembrolizumab

7. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Pharmacies
• 7.4. Retail Pharmacies

8. Americas PD-1 & PD-L1 Inhibitors Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific PD-1 & PD-L1 Inhibitors Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa PD-1 & PD-L1 Inhibitors Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Akeso Inc.
• 2. Alphamab Oncology
• 3. Amgen Inc.
• 4. AstraZeneca PLC
• 5. BeiGene Ltd.
• 6. Bristol Myers Squibb Company
• 7. Eli Lilly and Company
• 8. F. Hoffmann La Roche Ltd.
• 9. Gilead Sciences Inc.
• 10. GlaxoSmithKline PLC
• 11. Innovent Biologics Inc.
• 12. Merck KGaA
• 13. Novartis AG
• 14. Pfizer Inc.
• 15. Regeneron Pharmaceuticals Inc.
• 16. Sanofi S.A.